The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B
Abstract
Multiple endocrine neoplasia types 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinoma are dominantly inherited cancer syndromes. All three syndromes are associated with mutations in RET , which encodes a receptor-like tyrosine kinase. The altered RET alleles were shown to be transforming genes in NIH 3T3 cells as a consequence of constitutive activation of the RET kinase. The MEN2A mutation resulted in RET dimerization at steady state, whereas the MEN2B mutation altered RET catalytic properties both quantitatively and qualitatively. Oncogenic conversion of RET in these neoplastic syndromes establishes germline transmission of dominant transforming genes in human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells
Wigler, M., Silverstein, S., Lee, L.-S., Pellicer, A., Cheng, Y.-C., & Axel, R. (1977) · Cell · doi:10.1016/0092-8674(77)90333-6 · Cited by 1,352
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
Self-citationAntioncogenes and human cancer.
Knudson, A. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10914 · Cited by 762
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D., Kwok, J. B. J., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 652
Carlson, K. M., Dou, S., Chi, D., Scavarda, N., Toshima, K., Jackson, C. E., Wells, S. A., Goodfellow, P. J., & Donis-Keller, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1579 · Cited by 600
Takahashi, M., Buma, Y., Iwamoto, T., Inaguma, Y., Ikeda, H., & Hiai, H. (1988) · PubMed · Cited by 442
Cited by
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
McDermott, M. F., Aksentijevich, I., Galon, J., McDermott, E. M., Ogunkolade, B. W., Centola, M., Mansfield, E., Gadina, M., Karenko, L., Pettersson, T., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80721-7 · Cited by 1,408
Hirschsprung disease, associated syndromes and genetics: a review
Amiel, J., Sproat-Emison, E., Garcia-Barcelo, M., Lantieri, F., Burzynski, G., Borrego, S., Pelet, A., Arnold, S., Miao, X., Griseri, P., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.053959 · Cited by 1,206
Jing, S., Wen, D., Yu, Y., Holst, P. L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81311-2 · Cited by 1,174
GDNF signalling through the Ret receptor tyrosine kinase
Durbec, P., Marcos-Gutierrez, C. V., Kilkenny, C., Grigoriou, M., Wartiowaara, K., Suvanto, P., Smith, D., Ponder, B., Costantini, F., Saarma, M., et al. (1996) · Nature · doi:10.1038/381789a0 · Cited by 811
Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients
Joutel, A., Vahedi, K., Corpechot, C., Troesch, A., Chabriat, H., Vayssière, C., Cruaud, C., Maciazek, J., Weissenbach, J., Bousser, M.-G., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)08083-5 · Cited by 682
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Dahia, P. L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3648 · Cited by 545
Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1714 · Cited by 531
Naski, M. C., Wang, Q., Xu, J., & Ornitz, D. M. (1996) · Nature Genetics · doi:10.1038/ng0696-233 · Cited by 498
FLT3: ITDoes matter in leukemia
Levis, M., & Small, D. (2003) · Leukemia · doi:10.1038/sj.leu.2403099 · Cited by 495
Hirschsprung disease, associated syndromes, and genetics: a review
Amiel, J., & Lyonnet, S. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.729 · Cited by 479
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Self-citationRET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
The GDNF/RET signaling pathway and human diseases
Takahashi, M. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00012-0 · Cited by 446
Activating mutations for the Met tyrosine kinase receptor in human cancer
Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., & Vande Woude, G. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11445 · Cited by 442
Siegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Drilon, A., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.175 · Cited by 406
Highly penetrant hereditary cancer syndromes
Nagy, R., Sweet, K., & Eng, C. (2004) · Oncogene · doi:10.1038/sj.onc.1207714 · Cited by 380
Recognition and specificity in protein tyrosine kinase-mediated signalling
Songyang, Z., & Cantley, L. C. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89103-3 · Cited by 370
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
de Groot, J. W. B., Links, T. P., Plukker, J. T. M., Lips, C. J. M., & Hofstra, R. M. W. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0017 · Cited by 356
Vajo, Z., Francomano, C. A., & Wilkin, D. J. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.1.0387 · Cited by 350
RET Proto-Oncogene in the Development of Human Cancer
Eng, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.380 · Cited by 339
Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update
Wells, S. A., Pacini, F., Robinson, B. G., & Santoro, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1204 · Cited by 338
Self-citationThe RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease
Eng, C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609263351307 · Cited by 328
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
Xiao, S., Nalabolu, S. R., Aster, J. C., Ma, J., Abruzzo, L., Jaffe, E. S., Stone, R., Weissman, S. M., Hudson, T. J., & Fletcher, J. A. (1998) · Nature Genetics · doi:10.1038/ng0198-84 · Cited by 323
Evolution in Health and Disease
(2007) · doi:10.1093/acprof:oso/9780199207466.001.0001 · Cited by 320
FGFR activation in skeletal disorders: Too much of a good thing
Webster, M. (1997) · Trends in Genetics · doi:10.1016/s0168-9525(97)01131-1 · Cited by 317
The RET proto-oncogene in human cancers
Jhiang, S. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203857 · Cited by 298
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
Kouvaraki, M. A., Shapiro, S. E., Perrier, N. D., Cote, G. J., Gagel, R. F., Hoff, A. O., Sherman, S. I., Lee, J. E., & Evans, D. B. (2005) · Thyroid · doi:10.1089/thy.2005.15.531 · Cited by 288
Leboulleux, S., Baudin, E., Travagli, J., & Schlumberger, M. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02037.x · Cited by 281
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Subbiah, V., Yang, D., Velcheti, V., Drilon, A., & Meric-Bernstam, F. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02551 · Cited by 258
Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., Billaud, M., & Santoro, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207810 · Cited by 258
Self-citationFunctions of fibroblast growth factors and their receptors
O.M. Wilkie, A., Morriss-Kay, G. M., Yvonne Jones, E., & Heath, J. K. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00102-3 · Cited by 256
Pheochromocytoma: The expanding genetic differential diagnosis.
Bryant, J., Farmer, J., Kessler, L. J., Townsend, R. R., & Nathanson, K. L. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg024 · Cited by 250
Asai, N., Murakami, H., Iwashita, T., & Takahashi, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17644 · Cited by 184
Two B or not two B? overview of the rapidly expanding B-box family of proteins
Torok, M., & Etkin, L. D. (2001) · Differentiation · doi:10.1046/j.1432-0436.2001.067003063.x · Cited by 169
Dependence receptors: a new paradigm in cell signaling and cancer therapy
Goldschneider, D., & Mehlen, P. (2010) · Oncogene · doi:10.1038/onc.2010.13 · Cited by 169
Piao, X., & Bernstein, A. (1996) · Blood · doi:10.1182/blood.v87.8.3117.bloodjournal8783117 · Cited by 112
Signaling through Ras Is Essential for retOncogene-induced Cell Differentiation in PC12 Cells
Califano, D., Rizzo, C., D'Alessio, A., Colucci-D'Amato, G. L., Calı̀, G., Bartoli, P. C., Santelli, G., Vecchio, G., & de Franciscis, V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m905866199 · Cited by 67
Self-citationColucci-D'Amato, G. L., D'Alessio, A., Califano, D., Calı̀, G., Rizzo, C., Nitsch, L., Santelli, G., & de Franciscis, V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.25.19306 · Cited by 37
Metadata
- Authors
- Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., & Di Fiore, P. P.
- Venue
- Science
- Published
- 1995-01-20
- Volume
- 267
- Issue
- 5196
- Pages
- 381-383
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2128805986
- Cited by
- 841
- References
- 17
- FWCI
- 41.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.